Angioedema due to angiotensin-converting enzyme inhibitors
The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
Angiotensin-converting enzyme (ACE) inhibitor associated angioedema was detected in 39 subjects (17%) of 231 consecutive patients examined in the last 5 years at our out-patient clinic for symptoms of angioedema without urticaria. In these patients, angioedema was most commonly localized to the face. The duration of ACE-inhibitor treatment at the onset of angioedema ranged from 1 day to 8 years with a median of 6 months. The time elapsed between onset of angioedema and withdrawal of ACE-inhibitor ranged from 1 day to 10 years with a median of 10 months. Delayed diagnosis is explained by the unusual characteristics of this adverse reaction: angioedema may start years after beginning the treatment and then it recurs irregularly. In fact, ACE-inhibitors seem to facilitate angioedema in predisposed subjects, rather than causing it with an allergic or idiosyncratic mechanism. Thus, while Cl-inhibitor levels are usually normal in subjects developing ACE-inhibitor-dependent angioedema, we found that ACE-inhibitors caused angioedema in Cl-inhibitor-deficient patients. Because the main inactivator of bradykinin is kininase II, which is identical with ACE, it is believed that bradykinin mediates ACE-inhibitor-dependent angioedema. We had the possibility to examine the plasma bradykinin levels in one ACE-inhibitor-treated patient during an angioedema attack and we found very high levels, but we did not find an increase of break-down products of high-molecular-weight-kininogen as observed during acute attacks in hereditary angioedema. Bradykinin fell to normal levels during remission after withdrawal of the drug. These observations indicate that in ACE-inhibitor-induced angioedema, contrary to hereditary angioedema, the reduction of bradykinin catabolic rate plays a predominant role.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“An increase of BK has been measured in the plasma of patients during episodes of AE-ACEi, but, unlike hereditary forms of AE (MIM 106100), there is no increase in cleavage of the BK precursor, high-molecularweight kininogen (HK) (Nussberger et al. 1998; Agostoni et al. 1999; Cugno et al. 2003).”
From A variant in XPNPEP2 is associated with angioedema induced by angiotensin I-converting enzyme inhibitors. (2005) · cites this paper as Agostoni et al. 1999
Citations
Cites
Plasma bradykinin in angio-oedema
Nussberger, J., Cugno, M., Amstutz, C., Cicardi, M., Pellacani, A., & Agostoni, A. (1998) · The Lancet · doi:10.1016/s0140-6736(97)09137-x · Cited by 706
Self-citationClinical Profile of Angioedema Associated With Angiotensin Converting-Enzyme Inhibition
Slater, E. E. (1988) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1988.03410070095035 · Cited by 370
Brown, N. J., Ray, W. A., Snowden, M., & Griffin, M. R. (1996) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(96)90161-7 · Cited by 313
An enzyme in human blood plasma that inactivates bradykinin and kallidins
Erdös, E. G., & Sloane, E. M. (1962) · Biochemical Pharmacology · doi:10.1016/0006-2952(62)90119-3 · Cited by 305
ACE Inhibitor???Induced Angioedema: Incidence, Prevention and Management
Vleeming, W., van Amsterdam, J. G. C., Stricker, B. H., & de Wildt, D. J. (1998) · Drug Safety · doi:10.2165/00002018-199818030-00003 · Cited by 243
Prekallikrein Activation and High-Molecular-Weight Kininogen Consumption in Hereditary Angioedema
Schapira, M., Silver, L. D., Scott, C. F., Schmaier, A. H., Prograis, L. J., Curd, J. G., & Colman, R. W. (1983) · New England Journal of Medicine · doi:10.1056/nejm198305053081802 · Cited by 199
Angiotensin–converting enzyme (ACE) inhibitors and angio–oedema
Sabroe, R. A., & BLACK, A. K. (1997) · British Journal of Dermatology · doi:10.1111/j.1365-2133.1997.tb14887.x · Cited by 161
Angiotensin-converting enzyme (ACE) inhibitors and angio-oedema.
Sabroe, R. A., & BLACK, A. K. (1997) · PubMed · Cited by 142
Plasma Kinins Increase after Angiotensin-Converting Enzyme Inhibition in Human Subjects
Pellacani, A., Brunner, H. R., & Nussberger, J. (1994) · Clinical Science · doi:10.1042/cs0870567 · Cited by 133
Self-citationRecurrent Angiotensin-Converting Enzyme Inhibitor—Associated Angioedema
Brown, N. J. (1997) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1997.03550030072037 · Cited by 122
Cited by
Cicardi, M., Aberer, W., Banerji, A., Bas, M., Bernstein, J. A., Bork, K., Caballero, T., Farkas, H., Grumach, A., Kaplan, A. P., et al. (2014) · Allergy · doi:10.1111/all.12380 · Cited by 666
“On the other hand, continued use of ACEI in spite of angioedema results in a marked increase in the incidence of recurrent angioedema with serious morbidity (39, 40).”
BackgroundSelf-citationAgostoni, A., Aygören-Pürsün, E., Binkley, K. E., Blanch, A., Bork, K., Bouillet, L., Bucher, C., Castaldo, A. J., Cicardi, M., Davis, A. E., et al. (2004) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2004.06.047 · Cited by 646
“[97] [98] [99] [100] Given the important contribution of kinin inactivation pathways to the control of angioedema, this may be an avenue for further investigation.”
Self-citationAngiotensin-Converting Enzyme Inhibitors in Hypertension
Messerli, F. H., Bangalore, S., Bavishi, C., & Rimoldi, S. F. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.01.058 · Cited by 349
“Among all instances of angioedema, about 20% of cases are life-threatening, affecting the larynx and upper respiratory tract (49).”
BackgroundWAO Guideline for the Management of Hereditary Angioedema
Craig, T., Pürsün, E. A., Bork, K., Bowen, T., Boysen, H., Farkas, H., Grumach, A., Katelaris, C. H., Lockey, R., Longhurst, H., et al. (2012) · World Allergy Organization Journal · doi:10.1097/wox.0b013e318279affa · Cited by 346
Vasopeptidase Inhibitors: A New Therapeutic Concept in Cardiovascular Disease?
Corti, R., Burnett Jr, J. C., Rouleau, J. L., Ruschitzka, F., & Lüscher, T. F. (2001) · Circulation · doi:10.1161/hc4001.097191 · Cited by 300
Metadata
- Authors
- Agostoni, A., Cicardi, M., Cugno, M., Zingale, L. C., Gioffré, D., & Nussberger, J.
- Affiliations
- University of Milan (IT)
- Centre Hospitalier Universitaire Vaudois (CH)
- Corresponding author
- Agostoni, Angelo
- Venue
- Immunopharmacology
- Publisher
- Elsevier BV
- Published
- 1999-10
- Volume
- 44
- Issue
- 1-2
- Pages
- 21-25
- ISSN
- 0162-3109 (ISSN-L)
- OpenAlex
- W1991493178
- Cited by
- 147
- References
- 21
- Citations by year
- 2025: 6 · 2024: 2 · 2023: 2 · 2022: 3 · 2021: 3 · 2020: 4 · 2019: 7 · 2018: 5 · 2017: 5 · 2016: 7 · 2015: 4 · 2014: 8 · 2013: 5 · 2012: 6
- FWCI
- 4.37
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Locations
- Immunopharmacology (publishedVersion)
- PubMed (publishedVersion)
- IRIS (submittedVersion)
- SERVAL (Université de Lausanne) (submittedVersion)
- Topics
- Health Sciences › Medicine › Hematology › Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Renin-Angiotensin System Studies
- Life Sciences › Immunology and Microbiology › Immunology › Complement system in diseases
- Keywords
- ACE inhibitors, drug-induced angioedema, bradykinin, C1 inhibitor deficiency, hereditary angioedema, angiotensin-converting enzyme, high molecular weight kininogen, adverse drug reactions, delayed diagnosis
- MeSH terms
- Adolescent, Adult, Aged, Aged, 80 and over, Angioedema, Angiotensin-Converting Enzyme Inhibitors, Child, Child, Preschool, Female, Heart Failure, Humans, Hypertension, Male, Middle Aged, Recurrence
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Angioedema due to angiotensin-converting enzyme inhibitors. https://app.cochat.ai/papers/10.1016/s0162-3109(99)00107-1
- The paper
- Agostoni, A., Cicardi, M., Cugno, M., Zingale, L. C., Gioffré, D., & Nussberger, J. (1999). Angioedema due to angiotensin-converting enzyme inhibitors. Immunopharmacology. https://doi.org/10.1016/s0162-3109(99)00107-1
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.